The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).
作者信息
Guo Zong Sheng
机构信息
UPMC Hillman Cancer Center, Pittsburgh, PA, 15213, USA.
University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
出版信息
BMC Cancer. 2018 Nov 12;18(1):1086. doi: 10.1186/s12885-018-5020-3.
Abstract
摘要
相似文献
1
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).
BMC Cancer. 2018 Nov 12;18(1):1086. doi: 10.1186/s12885-018-5020-3.
2
Cancer treatment of today in view of the Nobel Prize.
Ups J Med Sci. 2018 Dec;123(4):205-206. doi: 10.1080/03009734.2018.1548528. Epub 2018 Dec 11.
3
[Cancer immunotherapy crowned with Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo].
Med Sci (Paris). 2019 Apr;35(4):365-366. doi: 10.1051/medsci/2019073. Epub 2019 Apr 30.
4
[From the time in the wilderness to the Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo: the Long March of cancer immunotherapy].
Med Sci (Paris). 2019 Apr;35(4):367-373. doi: 10.1051/medsci/2019074. Epub 2019 Apr 30.
5
Cancer immunologists scoop medicine Nobel prize.
Nature. 2018 Oct;562(7725):20-21. doi: 10.1038/d41586-018-06751-0.
6
The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize.
Virol Sin. 2018 Dec;33(6):467-471. doi: 10.1007/s12250-018-0077-3. Epub 2018 Dec 20.
7
Nobel notes value of basic research for new drugs.
Nature. 2018 Nov;563(7730):184. doi: 10.1038/d41586-018-07307-y.
8
A tribute to the life and career of Holbrook Kohrt.
Ann Oncol. 2016 Jul;27(7):1183-4. doi: 10.1093/annonc/mdw190. Epub 2016 May 10.
9
[2001 Nobel Prize for physiology or medicine].
Vopr Onkol. 2002;48(3):267-8.
10
The Nobel Prize laureate - father of anaphylaxis Charles-Robert Richet (1850-1935) and his anticancerous serum.
J BUON. 2011 Oct-Dec;16(4):783-6.
引用本文的文献
1
Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma.
Cancers (Basel). 2025 May 19;17(10):1702. doi: 10.3390/cancers17101702.
2
KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy.
Cancers (Basel). 2025 Feb 25;17(5):785. doi: 10.3390/cancers17050785.
3
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.
Korean J Clin Oncol. 2024 Dec;20(2):51-73. doi: 10.14216/kjco.24009. Epub 2024 Dec 31.
4
Monoclonal antibodies: From magic bullet to precision weapon.
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
5
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Pharmaceuticals (Basel). 2024 Jul 26;17(8):991. doi: 10.3390/ph17080991.
6
Editorial: Recent advances in gene modified immune cells and oncolytic virus for cancer immunotherapy.
Front Immunol. 2024 Jul 4;15:1454183. doi: 10.3389/fimmu.2024.1454183. eCollection 2024.
7
The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer.
Discov Oncol. 2024 Jun 25;15(1):244. doi: 10.1007/s12672-024-01117-7.
8
Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
World J Microbiol Biotechnol. 2024 May 17;40(7):204. doi: 10.1007/s11274-024-04018-7.
9
Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
PLoS One. 2024 May 14;19(5):e0303433. doi: 10.1371/journal.pone.0303433. eCollection 2024.
10
Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment.
Int J Nanomedicine. 2023 Dec 1;18:7149-7172. doi: 10.2147/IJN.S434582. eCollection 2023.
本文引用的文献
1
CAR T cell immunotherapy for human cancer.
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
2
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.
3
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
4
Converting Cold into Hot Tumors by Combining Immunotherapies.
Cell. 2017 Sep 7;170(6):1055-1056. doi: 10.1016/j.cell.2017.08.031.
5
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
6
An immunogenic personal neoantigen vaccine for patients with melanoma.
Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5.
7
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
Nat Commun. 2017 Mar 27;8:14754. doi: 10.1038/ncomms14754.
8
Coinhibitory Pathways in Immunotherapy for Cancer.
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
9
Adoptive cell transfer as personalized immunotherapy for human cancer.
Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
10
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Int Immunol. 2005 Feb;17(2):133-44. doi: 10.1093/intimm/dxh194. Epub 2004 Dec 20.
Zotero 插件